A069620 Stock Overview
Manufactures and sells pharmaceutical products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Daewoong Pharmaceutical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩125,000.00 |
| 52 Week High | ₩164,400.00 |
| 52 Week Low | ₩100,100.00 |
| Beta | 0.82 |
| 1 Month Change | -1.03% |
| 3 Month Change | -12.77% |
| 1 Year Change | 7.76% |
| 3 Year Change | -18.03% |
| 5 Year Change | -9.09% |
| Change since IPO | 940.12% |
Recent News & Updates
Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)
Nov 22
There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price
Nov 06Recent updates
Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)
Nov 22There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price
Nov 06Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly
Oct 15Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate
Aug 13Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings
Jul 24We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt
Jul 04Shareholder Returns
| A069620 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -3.0% | 1.0% | -0.9% |
| 1Y | 7.8% | 2.4% | -9.0% |
Return vs Industry: A069620 exceeded the KR Pharmaceuticals industry which returned 2.4% over the past year.
Return vs Market: A069620 exceeded the KR Market which returned -9% over the past year.
Price Volatility
| A069620 volatility | |
|---|---|
| A069620 Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A069620 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A069620's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1945 | 1,727 | Chang-Jae Lee | www.daewoong.com |
Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices.
Daewoong Pharmaceutical Co., Ltd Fundamentals Summary
| A069620 fundamental statistics | |
|---|---|
| Market cap | ₩1.44t |
| Earnings (TTM) | ₩103.57b |
| Revenue (TTM) | ₩1.42t |
13.9x
P/E Ratio1.0x
P/S RatioIs A069620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A069620 income statement (TTM) | |
|---|---|
| Revenue | ₩1.42t |
| Cost of Revenue | ₩692.09b |
| Gross Profit | ₩724.54b |
| Other Expenses | ₩620.96b |
| Earnings | ₩103.57b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.00k |
| Gross Margin | 51.15% |
| Net Profit Margin | 7.31% |
| Debt/Equity Ratio | 64.6% |
How did A069620 perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield7%
Payout RatioDoes A069620 pay a reliable dividends?
See A069620 dividend history and benchmarks| Daewoong Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Dec 27 2024 |
| Dividend Pay Date | Apr 14 2025 |
| Days until Ex dividend | 1 day |
| Days until Dividend pay date | 109 days |
Does A069620 pay a reliable dividends?
See A069620 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 20:04 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Daewoong Pharmaceutical Co., Ltd is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |
| Hyonseok Kim | CLSA |
| Heeyoung Lee | Daishin Securities Co. Ltd. |